ADAP Adaptimmune Therapeutics Plc

USD 0.88 0.00 0
Icon

Adaptimmune Therapeutics Plc (ADAP) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 0.88

0.00 (0.00)%

USD 0.22B

2.80M

USD 3.05(+246.59%)

USD 13.50 (+1434.09%)

Icon

ADAP

Adaptimmune Therapeutics Plc (USD)
COMMON STOCK | NSD
USD 0.88
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 0.22B

USD 13.50 (+1434.09%)

USD 0.88

Adaptimmune Therapeutics Plc (ADAP) Stock Forecast

Show ratings and price targets of :
USD 3.05
(+246.59%)

Based on the Adaptimmune Therapeutics Plc stock forecast from 3 analysts, the average analyst target price for Adaptimmune Therapeutics Plc is USD 3.05 over the next 12 months. Adaptimmune Therapeutics Plc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Adaptimmune Therapeutics Plc is Bearish, which is based on 1 positive signals and 5 negative signals. At the last closing, Adaptimmune Therapeutics Plc’s stock price was USD 0.88. Adaptimmune Therapeutics Plc’s stock price has changed by -15.38% over the past week, -20.72% over the past month and -13.73% over the last year.

No recent analyst target price found for Adaptimmune Therapeutics Plc
No recent average analyst rating found for Adaptimmune Therapeutics Plc

Company Overview Adaptimmune Therapeutics Plc

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPAS...Read More

https://www.adaptimmune.com

60 Jubilee Avenue, Abingdon, United Kingdom, OX14 4RX

449

December

USD

USA

Adjusted Closing Price for Adaptimmune Therapeutics Plc (ADAP)

Loading...

Unadjusted Closing Price for Adaptimmune Therapeutics Plc (ADAP)

Loading...

Share Trading Volume for Adaptimmune Therapeutics Plc Shares

Loading...

Compare Performance of Adaptimmune Therapeutics Plc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for ADAP

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Adaptimmune Therapeutics Plc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc 0.00 (0.00%) USD122.24B 30.78 20.00

ETFs Containing ADAP

Symbol Name ADAP's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Adaptimmune Therapeutics Plc (ADAP) Stock

Based on ratings from 3 analysts Adaptimmune Therapeutics Plc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 3 buy, sell and hold ratings.

Unfortunately we do not have enough data on ADAP's stock to indicate if its a good dividend stock.

Based on targets from 3 analysts, the average taret price for ADAP is USD 3.05 over the next 12 months. The maximum analyst target price is USD 3.15 while the minimum anlayst target price is USD 3.

Unfortunately we do not have enough data on ADAP's stock to indicate if its overvalued.

The last closing price of ADAP's stock was USD 0.88.

The most recent market capitalization for ADAP is USD 0.22B.

Based on targets from 3 analysts, the average taret price for ADAP is projected at USD 3.05 over the next 12 months. This means that ADAP's stock price may go up by +246.59% over the next 12 months.

We can't find any ETFs which contains Adaptimmune Therapeutics Plc's stock.

As per our most recent records Adaptimmune Therapeutics Plc has 449 Employees.

Adaptimmune Therapeutics Plc's registered address is 60 Jubilee Avenue, Abingdon, United Kingdom, OX14 4RX. You can get more information about it from Adaptimmune Therapeutics Plc's website at https://www.adaptimmune.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...